case
cluster
sever
acut
respiratori
infect
arabian
peninsula
tunisia
morocco
franc
itali
germani
uk
provid
full
descript
fatal
case
merscov
infect
associ
phylogenet
analys
report
data
patient
admit
klinikum
schwabe
munich
germani
sever
acut
respiratori
infect
diagnost
rtpcr
indirect
immunofl
uoresc
time
diagnosi
respiratori
faecal
urin
sampl
obtain
viru
quantifi
cation
construct
maximum
likelihood
tree
fi
avail
complet
merscov
genom
find
man
abu
dhabi
unit
arab
emir
transfer
klinikum
schwabe
march
day
ill
diagnos
multipl
myeloma
receiv
sever
line
treatment
patient
die
day
due
septic
shock
merscov
detect
two
sampl
bronchoalveolar
fl
uid
viral
load
highest
sampl
lower
respiratori
tract
copi
per
ml
maximum
viru
concentr
urin
sampl
rna
copi
per
ml
day
viru
present
urin
renal
failur
day
stool
sampl
obtain
day
contain
viru
rna
copi
per
g
close
lowest
detect
limit
assay
one
two
oronas
swab
obtain
day
posit
yield
littl
viral
rna
copi
per
ml
viru
detect
blood
full
viru
genom
combin
four
avail
full
genom
sequenc
maximum
likelihood
phylogeni
correl
branch
length
date
isol
time
common
ancestor
halfway
addit
novel
genom
data
unlink
case
treat
month
previous
essen
germani
show
cluster
virus
deriv
qatar
unit
arab
emir
interpret
provid
fi
rst
complet
viral
load
profi
le
case
merscov
infect
merscov
might
shed
pattern
diff
erent
sever
acut
respiratori
syndrom
might
need
altern
diagnost
approach
fund
june
coronaviru
belong
group
virus
previous
detect
bat
cultur
respiratori
secret
patient
die
sever
acut
respiratori
infect
agent
retrospect
detect
clinic
sampl
hospit
outbreak
sever
acut
respiratori
infect
occur
jordan
april
mark
fi
rst
known
occurr
viru
peopl
agent
name
middl
east
respiratori
syndrom
coronaviru
merscov
june
laboratoryconfi
rmed
case
report
jordan
saudi
arabia
uk
franc
itali
germani
tunisia
individu
laboratoryconfi
rmed
infect
die
virolog
data
becom
avail
merscov
case
inform
viral
genom
sequenc
could
identifi
import
epidemiolog
characterist
provid
full
descript
fatal
case
merscov
infect
import
munich
germani
abu
dhabi
includ
chronolog
profi
le
viru
concentr
divers
bodi
compart
fulli
sequenc
merscov
genom
therefor
could
chronolog
calibr
phylogenet
analysi
avail
merscov
genom
sequenc
data
complement
novel
sequenc
data
unlink
case
treat
germani
report
data
patient
admit
klinikum
schwabe
munich
germani
march
investig
done
part
public
health
intervent
accord
german
infect
protect
act
written
consent
scientifi
c
assess
obtain
patient
spous
part
patient
treatment
contract
diagnost
rtpcr
indirect
immunofl
uoresc
follow
recom
mendat
serum
neutralis
test
grew
vero
cell
subconfl
uenc
plate
preincub
reaction
contain
plaqueform
unit
merscov
emc
strain
medium
mix
onetoon
serum
sampl
patient
predilut
medium
start
dilut
tenth
h
incub
well
infect
h
total
preincub
reaction
supernat
remov
overlaid
avicel
resin
describ
herzog
colleagu
assay
termin
stain
day
defi
ned
neutralis
titr
serum
dilut
reduc
number
plaqu
four
parallel
well
summari
greater
antibodi
test
immunofl
uoresc
assay
clinic
materi
store
ward
laboratori
gather
submit
virolog
diagnost
test
time
laboratori
diagnosi
respiratori
faecal
urin
sampl
obtain
design
two
diff
erent
set
primer
gener
overlap
amplicon
avail
request
fi
rst
set
consist
amplicon
bp
length
primer
contain
two
strong
watsoncrick
bp
end
bind
templat
high
affi
niti
second
set
consist
amplicon
bp
length
primer
two
strong
bp
fi
termin
nucleotid
strong
pair
two
posit
method
primer
design
decreas
sensit
prevent
misprim
within
product
improv
success
amplifi
cation
rtpcr
sequenc
fragment
roch
junior
instrument
roch
penzberg
germani
assembl
geneiou
version
viru
quantifi
cation
done
standard
calibr
curv
base
quantifi
ed
invitro
transcrib
rna
upe
target
gene
construct
maximum
likelihood
tree
fi
avail
complet
merscov
genom
phyml
gtrgamma
model
molecular
evolut
assess
phylogenet
support
bootstrap
replic
infer
timescal
linear
regress
genet
diverg
root
time
collect
sampl
root
place
correl
coeffi
cient
maximis
phylogenet
tree
base
avail
merscov
sequenc
calcul
phyml
concaten
bp
dataset
hki
substitut
model
reduct
dataset
determin
small
number
sequenc
fragment
could
retriev
store
clinic
sampl
contain
small
amount
viru
deriv
patient
treat
essen
germani
sponsor
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
fi
nal
respons
submit
public
march
day
patienta
man
abu
dhabi
unit
arab
emiratesabruptli
develop
fl
ulik
symptom
fever
nonproduct
cough
admit
mafraq
hospit
abu
dhabi
day
fi
gure
diagnos
pneumonia
intub
day
progress
hypoxia
acut
respiratori
distress
syndrom
fraction
inspir
oxygen
posit
endexpiratori
pressur
cm
h
patient
receiv
intens
antimicrobi
treatment
meropenem
levofl
oxacin
vancomycin
caspofungin
aciclovir
oseltamivir
stay
intens
care
unit
abu
dhabi
without
major
improv
pulmonari
function
patient
transfer
klinikum
schwabe
munich
germani
march
fi
gure
patient
diagnos
multipl
myeloma
receiv
sever
line
treatment
previou
year
highdos
chemotherapi
autolog
stemcel
transplant
relaps
multipl
myeloma
novemb
given
lenalidomid
plu
dexamethason
rel
report
patient
own
camel
taken
care
diseas
anim
shortli
onset
symptom
anim
sampl
detail
potenti
sourc
exposur
could
retriev
stay
munich
record
thrombocytopenia
tabl
thrombocytopenia
also
report
fi
rst
describ
case
merscov
infect
two
four
patient
famili
cluster
saudi
arabia
two
case
report
franc
patient
develop
renal
insuffi
cienci
day
requir
dialysi
despit
continu
invas
ventil
antibiot
treatment
patient
health
statu
deterior
death
occur
day
due
septic
shock
sign
haemolysi
acut
coagul
disord
fi
gure
tabl
hospit
admiss
munich
infect
merscov
suspect
basi
treatmentrefractori
acut
respiratori
distress
syndrom
combin
geograph
origin
patient
bronchoalveolar
fl
uid
obtain
march
day
merscov
detect
sampl
rtpcr
also
detect
herp
simplex
viru
type
dna
copi
per
ml
rhinoviru
rna
copi
per
ml
rt
pcr
sampl
merscov
rna
concentr
respiratori
sampl
rang
genom
copi
per
ml
viru
concentr
seem
higher
sampl
taken
earlier
cours
obtain
later
fi
gure
concentr
variabl
tracheobronchi
sampl
bronchoalveolar
lavag
sampl
fi
gure
ascrib
variat
volum
salin
solut
appli
remov
tracheobronchi
sampl
notabl
suction
cathet
without
open
point
care
store
long
day
refriger
intens
care
unit
test
consist
posit
yield
roughli
lower
rna
concentr
fresh
tracheobronchi
aspir
taken
day
fi
gure
immunofl
uoresc
assay
yield
endpoint
titr
day
infect
tabl
igmspecifi
c
immunofl
uoresc
assay
confi
rmed
recent
infect
serum
sampl
tabl
plaquereduct
neutralis
test
confi
rmed
merscov
specifi
citi
detect
antibodi
titr
tabl
titr
somewhat
lower
record
serum
sampl
unlink
nonfat
case
merscov
treat
germani
serum
sampl
patient
taken
later
patient
tabl
test
two
urin
sampl
day
one
day
one
day
one
two
sampl
day
sampl
day
posit
mean
viru
present
urin
renal
failur
day
maximum
viru
concentr
rna
copi
per
ml
day
stool
sampl
obtain
day
fi
day
posit
rna
copi
per
g
concentr
close
lowest
detect
limit
assay
record
low
viru
concentr
one
two
oronas
aspir
sampl
taken
intub
patient
day
copi
per
ml
one
dialys
sampl
two
serum
sampl
day
one
serum
sampl
day
neg
although
obtain
sever
isol
herp
simplex
viru
type
repeat
attempt
isol
merscov
unsuccess
herp
simplex
viru
frequent
bystand
infect
intub
patient
known
aff
ect
cardiorespiratori
prognosi
outcom
sequenc
full
merscov
genom
directli
respiratori
sampl
genbank
access
number
subject
avail
merscov
genom
sequenc
phylogenet
analysi
includ
correl
regress
analysi
known
date
viru
isol
versu
tree
branch
length
fi
gure
estim
rate
evolut
substitut
per
site
per
year
time
common
ancestor
fi
virus
genom
avail
halfway
fi
gure
viru
patient
cluster
sequenc
viru
import
uk
qatar
compar
sequenc
anoth
viru
region
reanalys
store
clinic
sampl
anoth
case
merscov
infect
import
germani
octob
sampl
contain
low
concentr
rna
genom
viru
success
sequenc
previous
mani
attempt
recov
rtpcr
fragment
avail
bronchoalveolar
lavag
sampl
could
sequenc
fragment
cover
nucleotid
merscov
genom
genbank
access
number
concaten
align
homolog
sequenc
portion
avail
merscov
sequenc
subject
phylogenet
analys
confi
rming
cluster
sequenc
qatar
unit
arab
emir
fi
gure
sequenc
patient
histori
travel
pakistan
saudi
arabia
branch
next
cluster
day
cours
treatment
healthcar
worker
direct
contact
patient
patientderiv
materi
report
mild
respiratori
symptom
sampl
taken
upper
respiratori
tract
test
two
diff
erent
rtpcr
assay
merscov
none
yield
posit
result
contrast
one
patient
direct
contact
patient
merscov
infect
common
human
coronaviru
four
patient
infect
rhinovirus
rhinovirus
mutual
relat
none
relat
rhinoviru
detect
patient
merscov
appendix
followup
contact
patient
includ
investig
subclin
infect
progress
outlin
chronolog
followup
patient
merscov
use
quantit
virolog
diagnost
test
panel
viral
load
highest
lowerrespiratori
tract
viral
sequenc
patient
cluster
sequenc
nearbi
qatar
laboratori
data
crucial
diagnost
recommend
make
project
prognosi
estim
infect
risk
without
quantit
laboratori
data
well
document
case
merscov
infect
consider
made
basi
assum
analog
sever
acut
respiratori
syndrom
sar
howev
elementari
trait
viru
receptor
usag
sensit
type
type
iii
interferon
diff
er
substanti
sar
coronaviru
suggest
diff
erenc
diseas
pattern
eg
organ
tropism
viru
shed
might
exist
focus
aspect
quantit
viru
test
relev
bodi
compart
includ
viral
load
nonrespiratori
sampl
howev
patientlik
case
anecdot
report
farhad
underli
diseas
could
aff
ect
viru
shed
pattern
analysi
larg
number
patient
yield
gener
fi
gure
qualit
viru
data
faecal
shed
particular
interest
patient
sar
regularli
show
high
viru
concentr
prolong
viru
excret
stool
led
use
stool
sampl
even
routin
sar
diagnost
test
diarrhoea
report
two
descript
merscov
cluster
specul
faecal
viru
shed
might
occur
howev
laboratori
data
viru
stool
sampl
provid
patient
low
faecal
viru
concentr
close
lowest
detect
limit
day
ill
descript
far
one
stool
sampl
patient
merscov
neg
result
stool
sampl
mani
patient
includ
earli
stage
diseas
test
assess
whether
faecal
sourc
could
role
transmiss
whether
merscov
diff
er
sar
aspect
anoth
import
fi
nding
record
low
concentr
viru
urin
sampl
fi
nding
surpris
earli
kidney
failur
cours
merscov
infect
report
kidney
cell
laboratori
model
highli
permiss
merscov
replic
fact
viru
present
urin
blood
suggest
autonom
viru
replic
kidney
potenti
without
activ
secret
viru
urin
howev
renal
failur
due
specifi
c
viral
infect
immunopathogenesi
necessarili
indic
patient
receiv
sever
dose
potenti
nephrotox
antimicrobi
agent
set
underli
multipl
myeloma
postmortem
examin
urgent
need
clarifi
whether
kidney
failur
merscov
infect
primari
prevent
result
viral
infect
secondari
complic
sever
system
diseas
quantit
viru
data
need
orient
diagnost
hospit
infect
control
measur
record
viral
load
profi
le
highest
rna
concentr
bronchoalveolar
lavag
tracheobronchi
aspir
confi
rm
suggest
made
anoth
report
preferenti
use
lowerrespiratorytract
sampl
viru
diagnost
test
notabl
report
overal
stabil
detect
viru
rna
close
suction
cathet
indic
straightforward
noncontagi
way
collect
diagnost
sampl
even
nonintub
patient
oronas
swab
preferenti
submit
test
especi
patient
present
late
diseas
cours
substanti
lower
respiratori
involv
data
stool
urin
blood
sampl
suggest
fairli
low
infect
risk
nonrespiratori
care
procedur
absenc
detect
viru
blood
match
report
made
earlier
case
merscov
infect
howev
gueri
colleagu
report
low
semiquantit
viru
measur
blood
one
patient
moreov
initi
experiment
studi
suggest
merscov
infect
vascular
endotheli
cell
howev
quantit
data
suggest
low
risk
gener
laboratori
procedur
involv
blood
contrast
low
viru
concentr
failur
isol
infecti
viru
respiratori
secret
taken
gener
indic
airwayassoci
infect
risk
virolog
monitor
patient
start
late
diseas
cours
time
infecti
viru
could
alreadi
reduc
suggest
occurr
neutralis
antibodi
fact
could
isol
merscov
could
due
concomit
presenc
herp
simplex
viru
type
overgrew
diagnost
cell
cultur
search
pubm
report
publish
english
time
june
use
search
term
merscov
hcovemc
identifi
ed
report
link
middl
east
respiratori
syndrom
coronaviru
merscov
start
zaki
colleagu
initi
report
previous
unknown
coronaviru
isol
sputum
man
describ
use
search
term
merscov
identifi
ed
four
report
none
provid
quantit
viral
load
profi
le
infect
patient
report
provid
fi
rst
complet
viral
load
profi
le
case
merscov
infect
distribut
viral
load
respiratori
tract
suggest
lowerrespiratorytract
sampl
taken
preferenti
low
concentr
viru
stool
urin
blood
sampl
suggest
littl
viru
excretionat
least
patientfrom
bodi
compart
respiratori
tract
furthermor
coronavirus
infect
peopl
gener
diffi
cult
isol
particularli
late
phase
diseas
two
success
isol
merscov
report
worldwid
far
isol
done
day
diseas
day
diseas
sampl
taken
day
sampl
day
store
day
cell
cultur
isol
success
provid
inform
infecti
patient
even
highli
concentr
rhinoviru
seem
transmit
patient
suggest
eff
ectiv
protect
measur
place
treatment
intub
patient
intens
care
unit
sequenc
data
anoth
patient
treat
germani
enabl
extend
analysi
phylogeni
hint
geograph
structur
merscov
tree
specifi
calli
viral
sequenc
eastern
part
arabian
peninsula
cluster
togeth
stem
one
common
ancestor
whose
date
exist
project
virus
jeddah
jordan
date
estim
probabl
refi
ned
sequenc
becom
avail
moreov
whether
report
geograph
structur
repres
repeat
transfer
geograph
structur
viral
reservoir
popul
limit
chain
persontoperson
transmiss
multipl
sustain
lineag
human
infect
unclear
fi
complet
genom
sequenc
avail
yet
genet
data
urgent
need
establish
spatial
tempor
distribut
case
estim
number
independ
human
chain
transmiss
thu
better
assess
threat
merscov
pose
world
health
four
sequenc
continu
hospit
outbreak
alhasa
saudi
arabia
deposit
genbank
preliminari
phylogenet
analys
confi
rm
cluster
virus
eastern
part
arabian
peninsula
qatar
strain
essen
abu
dhabi
strain
munich
alhasa
genbank
access
number
cd
design
virolog
studi
phylogenet
analysi
virolog
data
analysi
ms
whar
gs
ss
wg
hgu
tr
msw
fb
cmw
contribut
clinic
data
gener
analysi
ms
vmc
rk
dm
sj
ar
contribut
fi
gure
vmc
rk
dm
sj
mam
sa
ud
gener
analys
virolog
data
ar
phylogenet
analysi
cd
whaa
hgo
cmw
interpret
data
cd
ms
vmc
fb
ar
cmw
wrote
report
whaa
advis
public
health
intervent
hgo
pg
coordin
public
health
intervent
declar
confl
ict
interest
